Latest Headlines

Latest Headlines

U.K. and CA companies to collaborate on breast cancer Dx study

The U.K.'s Abcodia will work with California-based OncoCyte to perfect a blood test for early breast cancer detection.

Gene-sequencing leukemia research could boost Dx and treatment for kids with a rare disease subtype

St. Jude Children's Research Hospital and colleagues from around the country used next-generation sequencing in a study that could upend how a high-risk leukemia subtype is diagnosed and treated in children and adolescents.

U.K. test may help Roche's cancer drug Avastin target ideal patients

Drugs such as Roche/Genentech's Avastin (bevacizumab) boost the survival odds of some ovarian cancer patients but not others. Researchers from The University of Manchester in the U.K. and colleagues believe they've developed a new blood test that can help find patients for whom the drug works best.

Bacteria injection shrinks tumors in animals

A bacteria-based injectable therapy shrunk tumors and completely eradicated others when tested in dogs and rats, according to a new study.

Cancer Genetics boosts Medicare coverage for DNA-based cancer Dx

Cancer Genetics isn't making money yet. But the New Jersey developer of DNA-based cancer diagnostics closed out its 2014 second quarter with smaller losses, some strategic acquisitions and a biomarker development partnership with AstraZeneca.

Investors become ambivalent to Biocept's Dx commercialization plans

Biocept recently released its 2014 second-quarter earnings as well as a corresponding update on the company's progress. Its results, which include much higher losses, highlight the molecular diagnostics player's aggressive strategy to achieve commercial success, and how far away it is from actually getting there.

Exact Sciences wins FDA approval and more for next-gen colon cancer test

Exact Sciences gained FDA premarket approval for its new, cutting-edge colorectal cancer screening test. It is also well ahead in the insurance reimbursement battle.

GE Healthcare vet to take on Biocept's Dx reimbursement strategy

Biocept is bringing on a veteran GE Healthcare and Quest Diagnostics executive to guide the company's insurance reimbursement and medical contract strategy.

Four biomarkers open door to possible esophageal cancer Dx

A U.S. research team has made progress toward creating a biomarker blood test that can detect esophageal cancer on the early side, a major need in order to combat the lethal disease.

Mice without regulator protein show longer life, fewer tumors

According to researchers at the Wistar Institute in Philadelphia, mice that lack a specific regulator protein live longer than mice that have it, a finding that sheds light on how metabolic networks might play a role in cancer treatment, aging and obesity.